Grifols (ES:GRF) has released an update.
Grifols, a leading healthcare company, has announced the successful allocation of EUR 1.6 billion from the sale of Shanghai RAAS equity to reduce upcoming debt maturities, thereby repaying all 2025 debt and leaving no further obligations until 2027. The company anticipates a leverage ratio improvement and a positive Free Cash Flow in Q2 2024, contributing to a strong liquidity forecast exceeding EUR 2.4 billion by the end of June 2024. Grifols emphasizes its solid financial position, with no connection to Scranton’s liabilities.
For further insights into ES:GRF stock, check out TipRanks’ Stock Analysis page.
